Medtronic submits this report to comply with fda regulations 21 cfr parts 4 and 803.Medtronic has made reasonable efforts to provide as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.Medtronic will submit a supplemental report if additional relevant information becomes known.
|
Medtronic received information that during the implant of this 25mm aortic bioprosthetic valve, it was explanted and replaced with a bioprosthetic valve of an different manufacturer.The reason for the replacement was reported as "bad leaflet coaptation, huge regurgitation." it was noted that the valve was not inspected prior to implant it, the incomplete coaptation was noticed after implantation, the sizers used were for the product and both the barrel end and replica end were used, a body surface area (bsa) chart was not used for valve sizing, the annulus was not felt to be between sizes, a root enlargement was not performed, pledgets were used, the valve was not re-sized following the pledget placement, it was the surgeons 3rd implantation with this product, and no clinical field support were present.No additional adverse patient effects were reported.
|